Retatrutide is a triple receptor agonist that targets the receptors of GIP, GLP-1, and glucagon hormones. By combining the effects of native GIP and GLP-1 with glucagon receptor activation, it exerts a broad appetite-suppressing and metabolic impact. Researchers suggest that this triple mechanism may offer more effective glycemic control and weight loss compared to other incretin-based therapies.
